One in five patients achieve functional hepatitis B cure after 24 weeks of bepirovirsen
medicalxpress - In an editorial published in the New England Journal of Medicine, University of Michigan Health hepatologist Anna S. Lok, M.D., hails newly announced results of the B-Well clinical trials as "a major step toward a functional cure for hepatitis B virus inf…
AI Summary: An antisense therapy, bepirovirsen, produced functional cures in roughly one in five patients after 24 weeks, driving cautious optimism for a finite treatment for chronic hepatitis B. The study demonstrated significant viral declines and serologic changes in a subset, prompting larger trials to confirm durability, safety, and which patients actually benefit.
Related Stories
Engineered 15‑strain biotherapeutic matches donor FMT for C. difficile / 2 months
Study finds MenB vaccine does not prevent gonorrhea in men / 7 wks
Antiviral ensitrelvir dramatically cuts household COVID transmission risk / 3 months
Triple‑dose early treatment clears HIV in newborn primates study / 15 days
Fridge‑free vaccine advances aim to cut massive vaccine wastage / 21 days
UK begins human testing of first AI-designed 'universal' vaccine / 2 months
Favipiravir shows promise in Lassa fever Phase 2 trial / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Medicare Advantage (not listed), Clinical Trials, Product Recall, Drug Pricing and look for the RSS link.
StackHealth Time Machine